Neoplasms

All Conditions

Symptoms and General Pathology

Digestive System Diseases

Carcinoma

Adenocarcinoma

Neoplasm Metastasis

Disease Progression

Colorectal Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Neoplastic Processes

Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Micronutrients

Hematinics

Vitamins

Amino Acids

Etoposide

Gemcitabine

Capecitabine

Vinorelbine

Paclitaxel

Irinotecan

Doxorubicin

Liposomal doxorubicin

Pemetrexed

Docetaxel

Cetuximab

Fluorouracil

Raltitrexed

Albumin-Bound Paclitaxel

Topotecan

Cisplatin

Oxaliplatin

Etoposide phosphate

Dasatinib

Mitomycins

Mitomycin

Sorafenib

Erlotinib Hydrochloride

Tubulin Modulators

Antimitotic Agents

Antimetabolites

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Immunosuppressive Agents

Immunologic Factors

Topoisomerase I Inhibitors

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Antineoplastic Agents, Immunological

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Alkylating Agents

Folinic Acid

Folate

Vitamin B9

Tyrosine

Control treatment and will be treated with any of the schemes used in the study according to the discretion of the physician.

Treatment guided by the gene expression profiles obtained from the CTC

Arm A chemotherapy

arm B chemotherapy

Carlos Gómez, M.D.,Ph.D

The purpose of this study is to assess the feasibility of selecting personalized therapies for colon cancer patients who have failed standard treatments, using a new methodology based on the determination of a profile of chemosensitivity by comprehensive genetic expression analysis from tumor samples.

It is a prospective, randomized study in patients with metastatic colorectal carcinoma progressing after two lines of prior therapy. Patients will be randomized (1:1) to receive chemotherapy as determined by its oncologist or treatment according to chemosensitivity profile obtained. For obtaining the profile a histological tumor sample and a sample of venous blood in a tube with heparin standard are necessary . This latter sample will be processed to isolate circulating tumor cells by cell adhesion with matrix coated glass spheres. The RNA from these circulating tumor cells as well as from tumor cells of tumor biopsies from the same patients will be extracted by a standard procedure for extracting RNA for genetic expression analysis. Based on the analysis performed on tumor biopsy is generated a ranked list of potentially more effective treatments in every case

Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic

Phase II Individualized Therapies Selection Study for Patients With Metastatic Colorectal Carcinoma According to the Genomic Expression Profile in Tumor Samples.

To determine the tumor progression-free survival at 3 and 6 months (PFS3 and PFS6) in both groups of patients and identify whether there is a statistically significant difference

Assess the correlation between the gene expression profiles obtained from the CTC and the gene expression profiles obtained from tumor samples from the same patients.

Hospital Universitario de Fuenlabrada

Grupo Hospital de Madrid

Apices Soluciones S.L.

Centro Nacional de Investigaciones Oncologicas CARLOS III

Spots Global Cancer Trial Database for arm b chemotherapy